Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for relapsed or refractory B-cell acute lymphoblastic leukemia
ChiCTR1800018210Phase 2Recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Sep 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoints: Minimal residual disease and Bone marrow response. Started Sep 2018; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR1800018210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018210.